Captivate Bio signs Distribution Agreement with Biological Industries
Agreement expands reach of cell culture and cytogenetic reagents for researchers and clinicians in the US.
June 17, 2021
WATERTOWN, MA – Captivate Bio, a scientific cell culture solutions provider, today announced it has signed a non-exclusive agreement with Biological Industries Israel Beit Haemek Ltd, now part of the Sartorius Group, to distribute its portfolio of cell culture and cytogenetic reagents in the United States. Under the terms, Captivate Bio will focus on expanding its reach, with unique products including the EZ-PCR™ Mycoplasma Detection Kit for detecting cell culture contamination and products used for the analysis of amniotic fluid, chorionic villus, peripheral blood, bone marrow and hematopoietic cells. Products will begin shipping in September.
“We are excited to be working with our friends at Biological Industries again. This partnership will significantly increase our commercial footprint in the US by providing products needed for genetic testing across the country,” stated Lori Oakes, Captivate Bio’s co-founder and managing partner. “Not only does this agreement expand customer access of BIO-HEMATO™, BIO-PB™, and BIO-AMF™ karyotyping reagents, but also general cell culture reagents and various serum-free media, including BIO-MPM™ and BIOTARGET™ for adherent cell culture.”
About Captivate Bio
Captivate Bio is a privately held scientific solutions provider specializing in the commercialization and distribution of high-quality reagents and custom cell culture media services for the research, therapeutic, and healthcare communities. Current product offering includes transport media and collection kits, classical cell culture media, animal sera including FBS, small molecules, human platelet lysate (HPL), and custom media manufacturing services for basic research, stem cell research, cell therapy, cytogenetics, and emerging markets such as cellular agriculture.
Tanya Potcova, CEO